pharmaphorum

APRIL 27, 2022

AstraZeneca and Daiichi Sankyo have claimed a fifth breakthrough designation from the FDA for Enhertu, shortly after showing the drug extended survival in patients with HER2-low metastatic breast cancer. The post Enhertu gets breakthrough tag in HER2-low breast cancer appeared first on. billion. .”

Chemotherapy 59

Chemotherapy 59

pharmaphorum

APRIL 5, 2022

Kimmtrak (tebentafusp) has been cleared to for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), mirroring its label in the US. Uveal melanoma is a rare cancer of the eye, which in the majority of patients is localised.

Labelling 52

Labelling Chemotherapy Immunity Immunization 52

pharmaphorum

MAY 17, 2021

There had been speculation that the FDA might approve Empaveli (pegcetacoplan) only as a backup option for patients who don’t see a sufficient benefit with Alexion’s Soliris (eculizumab) or Ultomiris (ravulizumab), but the regulator opted for a broad indication that included first-line treatment for PNH. billion and $1.1

Labelling 52

Labelling Vaccines 52

pharmaphorum

AUGUST 17, 2020

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Virtual connections. Engagement channels. Regulated industry learnings.

Communication 87

Communication Packaging Pharmaceutical Companies Pharmaceutical Companies 87

pharmaphorum

NOVEMBER 24, 2022

The phase 3 ESCAPE-TRD study in 676 patients revealed that significantly more of those treated with Spravato were able to achieve remission from symptoms of depression without a relapse over 32 weeks of follow-up compared to quetiapine. and 14.1%, respectively.

Labelling 52

Labelling Hospitals 52

Pharmaceutical Technology

MAY 2, 2023

Immuno-oncology (IO) agents have transformed the cancer therapeutics landscape, driving long-term remissions in a subset of patients who historically had limited options. Although a subset of patients derives long-term benefits from IO therapies, a high percentage of patients still fail to respond or develop resistance to IO therapy.

Immunity 52

Immunity Immunization Vaccines 52

pharmaphorum

JULY 25, 2022

The EMA’s human medicines committee has recommended approval of Johnson & Johnson’s Tecvayli as a fourth-line therapy for multiple myeloma , joining a growing group of BCMA-targeted therapies for the blood cancer. In the MagnetisMM-3 trial, elranatamab was associated with an ORR of 60.6%

52

52

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Of these patients, seven have been treated at the recommended phase II dose (RP2D) and regimen.

Drug Development 52

Drug Development Immunity Immunization Hospitals 52

PharmD Live

DECEMBER 21, 2021

Virtual care, normalized by the pandemic, is now common practice for providers and patients, especially at the primary care level–a boon in 2021 for underserved chronic care populations. With an annual price per patient of nearly $56,000 per year, patients’ families are looking for solutions for their loved ones–with a huge price tag.

Diabetes 52

Diabetes Hospitals 52

pharmaphorum

JUNE 8, 2021

The FDA “has failed in its responsibility to protect patients and families from unproven treatments with known harms” in approving Biogen’s Alzheimer’s disease drug Aduhelm. ICER points to brain swelling and potential bleeding seen in approximately 30% of patients treated with aducanumab. Broad label questioned.

Labelling 98

Labelling Drug Pricing 98

pharmaphorum

JANUARY 21, 2022

“It has become clear that the medicines of the 20 th century, the so-called blockbuster era, are gradually being replaced by drugs designed for smaller groups, specific indication, and even for individual patients,” said Jo De C**k, CEO of Belgium’s National Institute for Health and Disability Insurance. WHO is OMI?

Vaccines 52

Vaccines 52

epicur

DECEMBER 7, 2023

In this blog post, we’ll take a deeper look at the essentials of inventory management tailored specifically for veterinary practices—demand forecasting, the importance of streamlined systems and workflows, organization tips, and finding the perfect balance between practice needs and patient care. Let’s dive in!

Inventory Audits 52

Inventory Audits Labelling Hospitals Compounding 52

pharmaphorum

JUNE 2, 2021

NICE has rejected routine NHS funding for Roche’s Evrysdi (risdiplam) for spinal muscular atrophy drug in draft guidance, a decision which doesn’t come as a surprise to patient association SMA UK. The post NICE ‘no’ to Roche’s risdiplam for SMA not unexpected, says patient group appeared first on.

Documentation 52

Documentation Communication 52

European Pharmaceutical Review

AUGUST 24, 2022

there are 14 approved ADCs on the global market, all for oncology indications, and over 140 ADCs currently in clinical development” More than 20 years ago, the first ADC, Mylotarg, was approved for use in patients with relapsed or refractory acute myeloid leukaemia (AML). The culmination of two decades of learning.

Compounding 82

Compounding Pharmaceutical Companies Pharmaceutical Companies 82

PharmD Live

JANUARY 25, 2022

With the challenging number of diagnoses and medications that Medicare patients take, it is essential to have a team member whose primary function is to rapidly review patients records, give informed advice on any side effects to watch out for, and give medication interaction alerts to the rest of the care team.

Adverse Reactions 52

Adverse Reactions Doctor of Pharmacy Diabetes Communication 52

pharmaphorum

JUNE 2, 2022

When asked by pharmaphorum why product sales are expected to be so high in this area, a spokesperson for Evaluate explained: “For many rare diseases, there is high unmet need which results in high levels of use of orphan products in the eligible patient groups, and these groups are often larger than anticipated once treatments become available.

Compounding 52

Compounding Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 52

pharmaphorum

NOVEMBER 16, 2022

The advancements made in drug development over the last decade have seen the arrival of a number of treatments that offer one-time cures and more effective therapies for conditions in smaller patient populations. Advanced therapies have changed the treatment landscape for the industry and for patients. However, with a price tag of €1.58

Drug Development 130

Drug Development 130

PharmaShots

MARCH 9, 2023

She developed various mobile technologies and pioneered early electronic labels including NFC tags, which helped Thin Film Electronics win the Wall Street Innovation Award and the Global Technology Award. Designation: Chief Operating Officer (COO) Previous company: Getinge Group (7 yrs. LinkedIn Total experience: 16 yrs.

Clinical Pharmacology 40

Clinical Pharmacology Immunity Immunization Pharmaceutical Companies 40

pharmaphorum

MARCH 27, 2022

Carvykti – developed by J&J with China’s Legend Biotech – was approved on the back of a single arm, open-label, clinical trial in 113 patients – CARTITUDE-1 – which showed an overall response rate of 84%, with signs of the cancer disappearing altogether in 69% of recipients.

Labelling 91

Labelling Immunity Immunization 91

pharmaphorum

AUGUST 10, 2020

Roche has decided to price Evrysdi according to its weight, costing up to $340,000 per year, with the cost being under $100,000 annually for some younger patients. Evrysdi will be available in the US within two weeks for direct delivery to patients’ homes through Accredo Health Group, an Express Scripts specialty pharmacy.

Specialty Pharmacies 59

Specialty Pharmacies 59

pharmaphorum

JUNE 15, 2021

The adoption of New Science – a unique combination of the best in science and health technology that address significant unmet patient needs – is delivering more precise and effective treatments, but often at a higher price tag, according to new research. A new economic reality is challenging profitability .

Vaccines 90

Vaccines 90

pharmaphorum

FEBRUARY 26, 2021

During the 1990s, Ethicon’s Endo-Surgery pioneered minimally invasive surgery, which uses very small incisions and helps patients recover faster than with traditional surgery. Cordis was founded in Miami in 1959 and develops and produces medical equipment to treat patients who suffer from cardiovascular disease. billion in cash.

Vaccines 124

Vaccines Biosimilars Labelling Diabetes 124

RX Note

FEBRUARY 9, 2024

In outpatient pharmacy, we are trained to avoid medical jargons with patients. There are also times when patients describe symptoms in their native language (such as Mandarin), adding another layer to communication challenge. Analgesia 镇痛 - The removal of pain while a patient is conscious. My mind went blank for a moment.

Immunity 40

Immunity Immunization Diabetes Communication 40